Select Bibliography

Filter by any of these (after searching):

Gross, G.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

Roy, V. , LaPlant, B. R. , Gross, G. G. , Bane, C. L. ... - - Ann Oncol - 2009

Manuscript - Primary - Primary - Breast - NCCTG-0531

NCCTG phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC)

Roy, V. , Laplant, B. , Gross, G. , Palmieri, F. ... - - J Clin Oncol - 2007

Abstract - Primary - Primary - Breast - NCCTG-N0531

Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer, N1031 Alliance.

Sideras, K. , Moreno-Aspitia, A. , Tenglin, R. C. , Liu, H. ... - ASCO - J Clin Oncol - 2012

Abstract - Primary - Primary - Breast - NCCTG-N1031